22nd Century (XXII)

Overall impact
C (51)

Commentary

22nd Century is an average overall performer. With a 'C' rating of 50.9 for overall impact (43rd percentile compared to all companies), 22nd Century ranks 533rd out of 585 industry peers, behind Grifols, Biogen, Ionis Pharmaceuticals and 529 others, and ahead of Jazz Pharmaceuticals, Citius Pharmaceuticals, Celldex Therapeutics and 49 others. On top material causes for 22nd Century's industry (Pharmaceuticals & Biotech), 22nd Century performs well in Disease Eradication (95.7 score) and Child and Maternal Health (81.1) and performs poorly in Reduced Use of tobacco (0.0 score), Equal Pay and Opportunity (27.4), Disaster Readiness and Effective Aid (24.5) and 1 other cause where it received a 'D' or 'F' score.
Impact
Cause XXII
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
32
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Nc, United States
Share classes
XXII
Description
22nd Century Group, Inc., a tobacco products company, manufactures, distributes, and sells proprietary new reduced nicotine tobacco products in the United States. The company offers reduced nicotine content tobacco and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands, as well as turnkey contract manufacturing of cigarettes and filtered cigars for other established tobacco brands. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Mocksville, North Carolina.
Material causes
Ethos considers the following causes material for 22nd Century, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.